Skip to main content


2006 May
Stem cells for the repair and regenerationof bone
There continues to be a need for novel therapies directed at bone repair and regeneration in modern orthopaedics.
2007 July
Healing Full-Thickness Cartilage Defects Using Adipose-Derived Stem Cells.
The purpose of this study was to evaluate the use of adipose-derived stem cells (ADSCs) as a source for full-thickness cartilage repair in an animal model.
2009 January
Comparative Analysisof MesenchymalStem Cells from Bone Marrow,Umbilical Cord Blood, or Adipose Tissue
Mesenchymal stem cells (MSCs) represent a promising tool for new clinical concepts in supporting cellular therapy.
2012 March
Cite as Isolation, culture and chondrogenic differentiation of canine adipose tissue and bone marrow-derived mesenchymal stem cells–a comparative study.
In the dog, mesenchymal stem cells (MSCs) have been shown to reside in the bone marrow (bone marrow-derived mesenchymal stem cells: BM-MSCs) as well as in the adipose tissue (adipose tissue-derived stem cells: ADSCs).
2012 November
A Novel, Minimally-Invasive Technique of Cartilage Repair in the Human Knee Using Arthroscopic Microfracture and Injectionsof Mesenchymal Stem Cells andHyaluronic Acid - A ProspectiveComparative Study on Safety andShort-TermEfficacy.
Most current cell-based cartilage repair techniques require some form of scaffolds and 2 separate surgical procedures.
2013 April
Articular Cartilage Regeneration With Autologous Peripheral Blood Stem Cells Versus Hyaluronic Acid:A Randomized Controlled Trial.
The purpose of this study was to compare histologic and magnetic resonance imaging (MRI) evaluation of articular cartilage regeneration in patients with chondral lesions treated by arthroscopic subchondral drilling followed by postoperative intra-articular injections of hyaluronic acid (HA) with and without peripheral blood stem cells (PBSC).
2014 January
Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medialmeniscectomy: a randomized,double-blind, controlled study.
There are limited treatment options for tissue restoration and the prevention of degenerative changes in the knee.
2014 January
Effect of Intraarticular Injection ofAutologous Adipose-DerivedMesenchymal Stem and Regenerative Cells onClinical Signs of Chronic Osteoarthritisof the Elbow Joint in Dogs.
he field of adipose-derived mesenchymalstem cell (AD-MSC) therapy in regenerativemedicine is a rapidly growing area of research,and stem cell therapy is being used to treat os-teoarthritis (OA).
2014 January
Adipose-Derived Mesenchymal Stem Cellsfor the Treatment of Articular Cartilage:A Systematic Review on Preclinicaland Clinical Evidence.
Among the current therapeutic approaches for the regeneration of damaged articular cartilage, none has yet proven to offer results comparable to those of native hyaline cartilage.
2014 January
Intra‐Articular Injection of Mesenchymal StemCells for the Treatment ofOsteoarthritis of the Knee:A Proof‐of‐Concept Clinical Trial.
Mesenchymal stem cells (MSCs) are known to have a potential for articular cartilage regeneration. However, most studies focused on focal cartilage defect through surgical implantation.
2014 August
Does an Injection of a Stromal Vascular Fraction Containing Adipose-Derived Mesenchymal StemCells Influence the Outcomes of MarrowStimulation in Osteochondral Lesions of the Talus?:A Clinical and Magnetic Resonance Imaging Study.
Marrow stimulation for the treatment of osteochondral lesions of the talus (OLTs) is controversial in patients with poor prognostic factors of OLTs.
2015 January
Adipose-Derived Stromal Cells Protect Intervertebral Disc Cells in Compression: Implications for Stem Cell RegenerativeDisc Therapy.
Abnormal biomechanics plays a role in intervertebral disc degeneration. Adipose-derived stromal cells (ADSCs) have been implicated in disc integrity; however, their role in the setting of mechanical stimuli upon the disc's nucleus pulposus (NP) remains unknown.
2015 April
Regenerative Treatments to Enhance Orthopedic Surgical Outcome.
In orthopedic surgery there has been a never-ending quest to improve surgical outcome and the patient's experience.
2015 October
Immunoregulation of Bone Marrow-Derived Mesenchymal Stem Cells on the Chronic Cigarette Smoking-Induced Lung Inflammation in Rats.
mpact of bone mesenchymal stem cell (BMSC) transfusion on chronic smoking-induced lung inflammation is poorly understood.
2016 April
Biologic Treatments for Sports Injuries IIThink Tank—Current Concepts,Future Research, and Barriers to Advancement,Part 3.
Focal chondral defects of the articular surface are a common occurrence in the field of orthopaedics.
2016 May
Mesenchymal Stem Cells andTheir Clinical Applications in Osteoarthritis.
Osteoarthritis is a chronic degenerative joint disorder characterized by articular cartilage destruction and osteophyte formation.
2016 June
Cartilage tissue engineering: From biomaterials and stem cells toor Replace Knee Cartilage.
This guidance document provides to you, sponsors of an investigational device exemption application (IDE) or an investigational new drug application (IND), recommendations about certain information that should be included in a submission describing a product intended to repair or replace knee cartilage.
2016 June
Clinical Outcomes of MesenchymalStem Cell Injection With ArthroscopicTreatment in Older Patients With OsteochondralLesions of the Talus.
The ideal treatment for osteochondral lesions of the talus (OLTs) is still controversial, especially in older patients.Recently, mesenchymal stem cells (MSCs) have been suggested for use in the cell-based treatment of cartilage lesions.
2016 June
Osteoarthritis in Other Joints (Hip, Elbow, Foot, Ankle, Toes, Wrist) after SportsInjuries.
Osteoarthritis of nonknee joints, although less common than knee osteoarthritis, remains a significant and disabling condition for many present and former athletes.
2016 July
Human Multipotent Mesenchymal Stromal Cellsin the Treatment of Postoperative TemporalBone Defect: An Animal Model.
Canal wall down mastoidectomy is one of the most effective treatments for cholesteatoma.
2016 August
A multi-center analysis of adverse events among two thousand, three hundred and seventy twoadult patients undergoing adult autologous stem cell therapyfor orthopaedic conditions.
Autologous mesenchymal stem cells (MSCs) have been utilized to treat degenerative and post-traumatic orthopedic conditions for more than two decades.
2017 March
Mesenchymal stem cell therapy in the treatment ofhip osteoarthritis.
This study was performed to investigate the safety and efficacy of the intra-articular infusion of ex vivo expanded autologous bone marrow-derived mesenchymal stem cells (BM-MSC) to a cohort of patients with articular cartilage defects in the hip.
2017 April
Clinical efficacy and safety ofmesenchymal stem cell transplantation forosteoarthritis treatment: A meta-analysis.
The aim of this study was to evaluate the therapeutic efficacy and safety of mesenchymal stem cells (MSCs) for the treatment of patients with knee osteoarthritis (OA).
2017 August
Adipose derived stem cells for Orthopedic application: A new Frontier.
The application of appropriate cell origin for utilizing in regenerative medicine is the major issue. Various kinds of stem cells have been used for the tissue engineering and regenerative medicine.
2017 August
Adipose-derived stromal cell inregenerative medicine: A review
The application of appropriate cell origin for utilizing in regenerative medicine is the major issue. Various kinds of stem cells have been used for the tissue engineering and regenerative medicine.
2017 October
Autologous mesenchymal stem cells or meniscal cells: what is the best cell sourcefor regenerative meniscus treatmentin an early osteoarthritis situation?
Treatment of meniscus tears within the avascular region represents a significant challenge, particularly in a situation of early osteoarthritis.
2018 January
A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.
Osteoarthritis (OA) is a degenerative disease characterized by loss of cartilage and increased subchondral bone within synovial joints.
2018 July
Mesenchymal Stem Cells in Combinationwith Hyaluronic Acid for ArticularCartilage Defects.
Mesenchymal stem cells (MSCs) and hyaluronic acid (HA) have been found in previous studies to have great potential for medical use.
2018 August
Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis:A case-control study.
Colorectal cancer (CRC) is a common malignant gastrointestinal tumor.
2018 September
Identification of the Human Skeletal Stem Cell.
Stem cell regulation and hierarchical organization of human skeletal progenitors remain largely unexplored.
2018 September
Osteogenesis and aging: lessons from mesenchymal stem cells.
Aging is a high risk factor for the development of osteoporosis, a multifactorial age-related progressive disease characterized by reduced bone mass and increased risk of fractures.
2018 November
Limited evidence for adipose-derivedstem cell therapy on the treatment ofosteoarthritis.
The purpose of this systematic review is to evaluate the effects of adipose derived mesenchymal stem cells (ADSCs) in the treatment of osteoarthritis (OA) in the clinical setting.
2018 November
Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis.
Many pro-inflammatory pathways leading to arthritis have global effects on the immune system rather than only acting locally in joints.
2018 December
Chondrogenesis in a hyaluronic acidscaffold: comparison betweenchondrocytes and MSC from bone marrowand adipose tissue.
Treatment of focal lesions of the articular cartilage of the knee using chondrocytes in a hyaluronic acid (HA) scaffold is already being investigated in clinical trials.
2018 December
Umbilical Cord‐Derived Mesenchymal Stromal Cells (MSCs) for KneeOsteoarthritis: Repeated MSC Dosing IsSuperior to a Single MSC Dose and toHyaluronic Acid in a ControlledRandomized Phase I/II Trial
Knee osteoarthritis (OA) is a leading cause of pain and disability. Although conventional treatments show modest benefits, pilot and phase I/II trials with bone marrow (BM) and adipose‐derived (AD) mesenchymal stromal cells (MSCs) point to the feasibility, safety, and occurrence of clinical and structural improvement in focal or diffuse disease.